Active Ingredient History

  • Now
Bradanicline is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.   Wikipedia

  • SMILES: O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc3cccnc3)c4oc5ccccc5c4
  • Mol. Mass: 361.45
  • ALogP: 3.26
  • ChEMBL Molecule:
More Chemistry
bradanicline | n-(2-(pyridin-3-ylmethyl)-1-azabicyclo(2.2.2)oct-3-yl)-1-benzofuran-2-carboxamide | tc5619 | tc 5619 | tc-5619 | tc-5619-238


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue